ATLANTA — New trial results show that a drug candidate from Alnylam Pharmaceuticals can lead to long-lasting blood pressure reduction when taken with certain commonly used pills, but some doctors are questioning how much the drug would actually be used in clinical practice.
Zilebesiran, a novel RNA interference drug dosed every six months, is intended to address a long-standing problem: despite the availability of cheap pills to lower blood pressure, there are still high rates of uncontrolled hypertension in part because people aren’t good at regularly taking their daily pills.
In a Phase 2 trial, patients with uncontrolled hypertension had 12.1 mmHg and 9.7 mmHg lower ambulatory blood pressure at three months when taking the drug in combination with the daily pills indapamide and amlodipine, respectively, compared with people taking the pills alone, according to data presented on Sunday here at the American College of Cardiology meeting.
Click this link for the original source of this article.
Author: Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.